Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Jae Yoon Jeon"'
Autor:
Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker, Erin Hertlein, John C. Byrd
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-14 (2020)
Abstract Background Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) including Src and Lyn, spl
Externí odkaz:
https://doaj.org/article/dd45c2eb4bd348c99ba2f63a9ee816cc
Autor:
Christina D. Drenberg, Anang Shelat, Jinjun Dang, Anitria Cotton, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Qiang Fu, Daelynn R. Buelow, Marissa Pioso, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy, Sharyn D. Baker
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Pediatric AML is traditionally treated with chemotherapy and stem cell transplant but some subsets of patients have a poor response to therapy. Here, the authors perform a high throughput screen and identify several FDA approved drugs that might be u
Externí odkaz:
https://doaj.org/article/f909cbdab341455d9f702b6081a46e6f
Autor:
Jae Yoon Jeon, Daelynn R. Buelow, Dominique A. Garrison, Mingshan Niu, Eric D. Eisenmann, Kevin M. Huang, Megan E. Zavorka Thomas, Robert H. Weber, Clifford J. Whatcott, Steve L. Warner, Shelley J. Orwick, Bridget Carmichael, Emily Stahl, Lindsey T. Brinton, Rosa Lapalombella, James S. Blachly, Erin Hertlein, John C. Byrd, Bhavana Bhatnagar, Sharyn D. Baker
Publikováno v:
JCI Insight, Vol 5, Iss 23 (2020)
Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling,
Externí odkaz:
https://doaj.org/article/4bacc087740b4a43a3e2e850f46e9e4b
Autor:
Jamie A. Jarusiewicz, Jae Yoon Jeon, Michele C. Connelly, Yizhe Chen, Lei Yang, Sharyn D. Baker, R. Kiplin Guy
Publikováno v:
ACS Omega, Vol 2, Iss 5, Pp 1985-2009 (2017)
Externí odkaz:
https://doaj.org/article/9d9d69bd85a14a19a62e610d164389a8
Autor:
Megan E. Zavorka Thomas, Navjot Pabla, Daelynn R. Buelow, Sharyn D. Baker, Alex Sparreboom, Jae Yoon Jeon, Josie A. Silvaroli, Moray J. Campbell, Zahra Talebi
Publikováno v:
Blood Advances. 5:5041-5046
Drug resistance and relapse are common challenges in acute myeloid leukemia (AML), particularly in an aggressive subset bearing internal tandem duplications (ITDs) of the FLT3 receptor (FLT3-ITD+). The tyrosine kinase inhibitor gilteritinib is approv
Autor:
Eric D. Eisenmann, Jack C. Stromatt, Sydney Fobare, Kevin M. Huang, Daelynn R. Buelow, Shelley Orwick, Jae Yoon Jeon, Robert H. Weber, Bill Larsen, Alice S. Mims, Erin Hertlein, John C. Byrd, Sharyn D. Baker
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 29
Acute myeloid leukemia (AML) with mutations in the tumor suppressor gene TP53 confers a dismal prognosis with 3-year overall survival of
Autor:
Jae Yoon Jeon, Alice A. Gibson, Alex Sparreboom, Xiyuan Lu, Alessia Lodi, Julie Nguyen, Sharyn D. Baker, Meghan Collins, Douglas H. Sweet, Zahra Talebi, Muhammad Erfan Uddin, Daelynn R. Buelow, Rosa Lapalombella, Shannon R. Sweeney, Moray J. Campbell, Stefano Tiziani, Megan E. Zavorka Thomas, Lindsey T. Brinton
Publikováno v:
Molecular Cancer Therapeutics. 20:2207-2217
Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy associated with frequent relapse and poor overall survival. The tyrosine kinase inhibitor gilteritinib is approved for t
Autor:
Daelynn R. Buelow, Bhavana Bhatnagar, Shelley J. Orwick, Jae Yoon Jeon, Eric D. Eisenmann, Jack C. Stromatt, Navjot Singh Pabla, James S. Blachly, Sharyn D. Baker, Bradley W. Blaser
Publikováno v:
Blood advances. 6(17)
Despite the clinical benefit associated with gilteritinib in relapsed/refractory acute myeloid leukemia (AML), most patients eventually develop resistance through unknown mechanisms. To delineate the mechanistic basis of resistance to gilteritinib, w
Publikováno v:
Pharmaceutical research. 39(8)
The approval of four small interfering RNA (siRNA) products in the past few years has demonstrated unequivocally the therapeutic potential of this novel modality. Three such products (givosiran, lumasiran and inclisiran) are liver-targeted, using tri
Autor:
Kevin M. Huang, Erin Hertlein, Bill Larsen, Robert J. Weber, Daelynn R. Buelow, John C. Byrd, Josie A. Silvaroli, Sharyn D. Baker, Shelley Orwick, Eric D. Eisenmann, Sydney Fobare, Jae Yoon Jeon, Jack Stromatt
Publikováno v:
The FASEB Journal. 35